Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the drug's maximum non-toxic dose as well as examine potential genetic, reproductive, and carcinogenic effects. Animals are treated with the drug for a specified duration and closely monitored for adverse effects. Post-mortem examinations are conducted to detect any signs of tissue damage. Efforts have been made to reduce animal usage through in vitro methods and computer modeling, although their predictive value is still limited.

The third phase involves pharmacokinetic and pharmacodynamic (PK/PD) testing, which studies the drug's absorption, metabolism, distribution, and elimination in laboratory animals. These studies help establish the relationship between drug exposure and its effects. The fourth phase is chemical and pharmaceutical development, which focuses on synthesizing the compound on a large scale, assessing its stability, and developing a formulation suitable for clinical studies.

Approximately half of the identified drug candidates fail during preclinical development. For the remaining candidates, a detailed dossier called the "investigator brochure" is prepared along with study protocols for submission to regulatory authorities such as the European Medicines Agency or the US FDA. Permission from the regulatory authority is required to proceed with human studies. The authority may refuse permission or request further work before granting approval.

Tags
Preclinical DevelopmentTherapeutic CompoundSafety PharmacologyToxicological TestingMaximum Non toxic DosePharmacokineticsPharmacodynamicsChemical DevelopmentPharmaceutical DevelopmentInvestigator BrochureRegulatory AuthoritiesEuropean Medicines AgencyUS FDA

Aus Kapitel 1:

article

Now Playing

1.2 : Preclinical Development: Overview

General Pharmacological Principles

3.5K Ansichten

article

1.1 : Drug Discovery: Überblick

General Pharmacological Principles

6.5K Ansichten

article

1.3 : Klinische Studien: Überblick

General Pharmacological Principles

2.0K Ansichten

article

1.4 : Nomenklatur des Arzneimittels

General Pharmacological Principles

1.3K Ansichten

article

1.5 : Arzneimittelregulierung

General Pharmacological Principles

1.0K Ansichten

article

1.6 : Medikamentenklassen und -kategorien

General Pharmacological Principles

1.6K Ansichten

article

1.7 : Wirkstoff-Rezeptor-Bindungen

General Pharmacological Principles

2.3K Ansichten

article

1.8 : Wechselwirkungen zwischen Arzneimitteln und Rezeptoren

General Pharmacological Principles

4.2K Ansichten

article

1.9 : Wege der Arzneimittelverabreichung: Überblick

General Pharmacological Principles

3.2K Ansichten

article

1.10 : Wege der Arzneimittelverabreichung: Enteral

General Pharmacological Principles

2.8K Ansichten

article

1.11 : Wege der Arzneimittelverabreichung: Parenteral

General Pharmacological Principles

1.7K Ansichten

article

1.12 : Zusätzliche Wege der Arzneimittelverabreichung

General Pharmacological Principles

1.7K Ansichten

article

1.13 : Verschreibungspflichtige, nicht verschreibungspflichtige und Orphan Drugs

General Pharmacological Principles

574 Ansichten

article

1.14 : Faktoren, die das Ansprechen auf Medikamente beeinflussen: Überblick

General Pharmacological Principles

1.5K Ansichten

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten